Evidence map›Paper›PMID 26796672›Full record

ReviewAmerican journal of respiratory cell and molecular biology2016

Transforming Growth Factor-β: Master Regulator of the Respiratory System in Health and Disease.

Yael Aschner, Gregory P Downey

Abstract readReview
In one paragraph

Review in American journal of respiratory cell and molecular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 160 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 1 synthesis or guideline pooled it, 241 citations in OpenAlex.

  1. Pooled it
  2. Dual αAmerican journal of respiratory and critical care medicine · 2025
    Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Regulation of inflammatory lung injury and repair by transforming growth factors.American journal of physiology. Lung cellular and molecular physiology · 2025
    Review
  18. TGF-β induces excessive pulmonary IL-6 secretion in cystic fibrosis via PI3K.American journal of physiology. Lung cellular and molecular physiology · 2025
    Article
  19. Article
  20. Article

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Yael Aschner1 Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, and.
Gregory P Downey1 Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, and.
National Jewish Health · USPulmonary and Critical Care Associates · US

Funding

Checkpoint Function of PTPalpha in Pathological Fibrogenesis in the LungR01HL132950 · NHLBI · NATIONAL JEWISH HEALTH · PI DOWNEY, GREGORY PAUL · 2016 to 2019
$2.0M
Targeting PTPalpha to Prevent Lung FibrosisR21ES023932 · NIEHS · NATIONAL JEWISH HEALTH · PI DOWNEY, GREGORY PAUL · 2014 to 2015
$436k
NHLBI NIH HHS R01 HL132950NIEHS NIH HHS R21 ES023932
6 · The paper itself

Abstract

In this article, we review the biology and physiological importance of transforming growth factor-β (TGF-β) to homeostasis in the respiratory system, its importance to innate and adaptive immune responses in the lung, and its pathophysiological role in various chronic pulmonary diseases including pulmonary arterial hypertension, chronic obstructive pulmonary disease, asthma, and pulmonary fibrosis. The TGF-β family is responsible for initiation of the intracellular signaling pathways that direct numerous cellular activities including proliferation, differentiation, extracellular matrix synthesis, and apoptosis. When TGF-β signaling is dysregulated or essential control mechanisms are unbalanced, the consequences of organ and tissue dysfunction can be profound. The complexities and myriad checkpoints built into the TGF-β signaling pathways provide attractive targets for the treatment of these disease states, many of which are currently being investigated. This review focuses on those aspects of TGF-β biology that are most relevant to pulmonary diseases and that hold promise as novel therapeutic targets.

Indexed as

HealthAnimalsHomeostasisHumansRespiratory SystemRespiratory Tract DiseasesSignal TransductionTransforming Growth Factor betaTransforming Growth Factor betaasthmaCOPDfibroblastpulmonary arterial hypertensionpulmonary fibrosis

Identifiers

PMID26796672
PMCPMC4942197
OpenAlexW2271349749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.